Published in Managed Care Weekly Digest, November 1st, 2004
Rebif, co-marketed by the two companies, is a disease-modifying drug given three times per week by self-injection that has been proven to delay the progression of disability associated with relapsing forms of multiple sclerosis.
The nursing system, called The MS LifeLines Nurse Educators, will help teach Rebif patients about the importance of their therapy and how to administer it. According...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Weekly Digest
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.